Text Size

The Role of ITGAM in Systemic Lupus Erythematosus

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier:
NCT01230112
First received: October 27, 2010
Last updated: January 4, 2012
Last verified: January 2012
History of Changes
  Purpose

Study to examine the role of ITGAM molecule in normal control subjects with known genetic variation in the ITGAM gene.


Condition
Systemic Lupus Erythematosus

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: TAP0307.6: Sub-study of TAP 0307- Enrollment of Normal Controls to Study the Role of ITGAM in Systemic Lupus Erythematosus

Resource links provided by NLM:

MedlinePlus related topics: Lupus
U.S. FDA Resources

Further study details as provided by North Shore Long Island Jewish Health System:

Biospecimen Retention:   Samples With DNA

Blood and DNA will be collected and retained


Enrollment: 40
Study Start Date: December 2009
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Normal Control Subjects with genotype of interest registered in the Genotype and Phenotype Registry

Criteria

Inclusion Criteria:

  • males and females, age 18 or older, enrolled in Genotype and Phenotype Registry, in general good health
  • Participants who carry the genotype of interest, based on a buccal or blood derived DNA sample

Exclusion Criteria:

  • History of Systemic Lupus Erythematosus, rheumatoid arthritis, or other autoimmune disease
  • History of cancer or lymphoma
  • Current use of aspirin, prednisone, or NSAID or any immunosuppressant
  • Self reported HIV
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01230112

Locations
United States, New York
Feinstein Institute for Medical Research
Manhasset, New York, United States, 11030
Sponsors and Collaborators
North Shore Long Island Jewish Health System
National Institute of Allergy and Infectious Diseases (NIAID)
  More Information

No publications provided

Responsible Party: North Shore Long Island Jewish Health System
ClinicalTrials.gov Identifier: NCT01230112     History of Changes
Other Study ID Numbers: 09-289
Study First Received: October 27, 2010
Last Updated: January 4, 2012
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on May 19, 2013